Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Lipella Pharmaceuticals's 3-Year RORE % for the quarter that ended in Sep. 2025 was -28.34%.
The industry rank for Lipella Pharmaceuticals's 3-Year RORE % or its related term are showing as below:
LIPO's 3-Year RORE % is ranked worse than 67.29% of 1293
companies
in the Biotechnology industry
Industry Median: -11.55
vs LIPO: -28.34
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Lipella Pharmaceuticals 3-Year RORE % Related Terms
Lipella Pharmaceuticals 3-Year RORE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LIPO vs IOBTQ, WINT, CYTOF: 3-Year RORE % Comparison
For the Biotechnology subindustry, Lipella Pharmaceuticals's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lipella Pharmaceuticals 3-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lipella Pharmaceuticals's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Lipella Pharmaceuticals's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Sep. 2025 and 3-year before.
Lipella Pharmaceuticals (LIPO) has a 3-Year RORE % of -28.34 as of Sep. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Lipella Pharmaceuticals and its competitors. According to the industry distribution chart, Lipella Pharmaceuticals ranks #870 out of 1293 companies in the Biotechnology industry, placing it in the top 67.3%.
Is Lipella Pharmaceuticals' 3-Year RORE % too high?
Lipella Pharmaceuticals' current 3-Year RORE % is -28.34. Based on the distribution chart, Lipella Pharmaceuticals ranks #870 out of 1293 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Lipella Pharmaceuticals has a GF Score™ of 35/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lipella Pharmaceuticals' 3-Year RORE % compare to IOBTQ and WINT?
According to the Biotechnology industry distribution chart, Lipella Pharmaceuticals ranks #870 out of 1293 companies for 3-Year RORE %. This places Lipella Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Biotechnology company?
A good 3-Year RORE % depends on the Biotechnology industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Lipella Pharmaceuticals and its competitors. Lipella Pharmaceuticals's current 3-Year RORE % is -28.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lipella Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Lipella Pharmaceuticals (LIPO) is currently considered Possible Value Trap. The stock's GF Value™ is $8.69, compared to a current price of $0.13 — trading 98.5% below its estimated fair value. The current 3-Year RORE % is -28.34. Lipella Pharmaceuticals' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Lipella Pharmaceuticals (LIPO), the current 3-Year RORE % is -28.34 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lipella Pharmaceuticals (LIPO) Overvalued in 2026?
Based on GuruFocus' analysis, Lipella Pharmaceuticals stock appears to be undervalued.
The current stock price of $0.13 is trading 98.5% below its estimated GF Value™ of $8.69.
GuruFocus considers Lipella Pharmaceuticals to be Possible Value Trap.
Key valuation signals for LIPO:
3-Year RORE %: -28.34
GF Value™: $8.69 vs. price of $0.13 (98.5% below fair value)
No single metric tells the full story. See the LIPO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410, which can be helpful in the treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.
35GF Score
Get the complete analysis for LIPO
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LIPO has been successfully added to your 
